endocrine therapy

Elacestrant Reinforces Its Role in the Real-World Management of ESR1-Mutated Metastatic Breast Cancer

By MedXY 01/08/2026

This real-world study demonstrates that elacestrant provides a durable benefit for patients with ER+/HER2- ESR1-mutated metastatic breast cancer, maintaining efficacy across various treatment lines and in patients with visceral metastases or co-occurring PI3K mutations.

Neurology news Oncology

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status

By MedXY 12/17/2025

A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.

news Oncology

Breast Cancer Index in Premenopausal HR+ Disease: Prognostic Confirmed, Predictive Role for OFS-Intensification Context-Dependent

By MedXY 12/15/2025

Two large prospective‑retrospective analyses confirm BCI as a robust prognostic biomarker in premenopausal HR+ breast cancer; its HOXB13/IL17BR (H/I) component predicted benefit from adding ovarian function suppression versus tamoxifen alone but did not clearly predict superiority of exemestane+OFS over tamoxifen+OFS.

OB/GYN & Women's Health Oncology Specialties

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY 08/21/2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

news OB/GYN & Women's Health Oncology Specialties

Extending Endocrine Treatment Duration for Early Breast Cancer

By MedXY 08/19/2025

This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.